The Impact of the Third Wave of COVID 19 in Patients with Chronic Hepatitis C

Daniela Mariano Carvalho-Louro
{"title":"The Impact of the Third Wave of COVID 19 in Patients with Chronic Hepatitis C","authors":"Daniela Mariano Carvalho-Louro","doi":"10.33597/jcpt-01-id1003","DOIUrl":null,"url":null,"abstract":"Letter to EditorIn the practical clinical of Hepatology, the focus of daily life has been the treatment of patients with severe liver diseases, such as cirrhosis and liver cancer. Of all the liver diseases responsible for cirrhosis development, hepatitis C had made the most treatment progress. In a few years, it evolved from drugs with low efficacy and many side effects to highly safe medications with high cure rates.For hepatologists who manage critically ill patients with advanced stages of liver diseases, finding an effective Hepatitis C drug was a great encouragement, a huge motivation to continue believing in clinical research.","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33597/jcpt-01-id1003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Letter to EditorIn the practical clinical of Hepatology, the focus of daily life has been the treatment of patients with severe liver diseases, such as cirrhosis and liver cancer. Of all the liver diseases responsible for cirrhosis development, hepatitis C had made the most treatment progress. In a few years, it evolved from drugs with low efficacy and many side effects to highly safe medications with high cure rates.For hepatologists who manage critically ill patients with advanced stages of liver diseases, finding an effective Hepatitis C drug was a great encouragement, a huge motivation to continue believing in clinical research.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
第三波COVID - 19对慢性丙型肝炎患者的影响
在肝病临床实践中,日常生活的重点一直是肝硬化、肝癌等严重肝病患者的治疗。在所有导致肝硬化发展的肝病中,丙型肝炎的治疗进展最大。在几年的时间里,它从低疗效和许多副作用的药物发展到高治愈率的高度安全的药物。对于管理晚期肝病重症患者的肝病学家来说,找到一种有效的丙型肝炎药物是一个巨大的鼓励,是继续相信临床研究的巨大动力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
28
期刊最新文献
Pharmacokinetics and Safety of Tucatinib in Healthy Japanese and Caucasian Volunteers: Results From a Phase Ⅰ Study 2020 年度日本臨床薬理学会海外研修員報告: 研修完了報告書 Safety, Tolerability, and Pharmacokinetics of Belumosudil, a Selective Rho-associated Coiled-coil-containing Protein Kinase 2 Inhibitor, in Healthy Japanese Volunteers: A PhaseⅠ, Randomized, Controlled Trial 第 7 回 日本臨床薬理学会 東海・北陸地方会を終えて 2021 年度日本臨床薬理学会海外研修員報告: 研修完了報告書
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1